RN-0191 is under clinical development by Ikaria Bioscience and currently in Phase I for Hypercholesterolemia. According to GlobalData, Phase I drugs for Hypercholesterolemia have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RN-0191’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RN0191 is under development for the treatment of hypercholesteremia. The therapeutic candidate is administered through subcutaneous route.
Ikaria Bioscience overview
Ikaria Bioscience is a healthcare provider which is specialized in the treatment of metabolic disorders and offers other services. It is headquartered in Notting Hill, Victoria, Australia.
For a complete picture of RN-0191’s drug-specific PTSR and LoA scores, buy the report here.